Understanding how SARS-CoV-2 Spike proteins interact with antibodies
In situ structures of SARS-CoV-2 Spike fusion intermediates and Spike-antibody-Fc receptor complexes
This study is looking at a part of the virus that causes COVID-19 to understand how it helps the virus enter our cells, with the hope of finding new ways to create better treatments and vaccines for everyone.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11002280 on NIH RePORTER |
What this research studies
This research investigates the structures of the SARS-CoV-2 Spike protein, particularly focusing on its S2 domain, which is crucial for the virus's ability to enter human cells. By examining how this protein changes shape during the infection process, the study aims to identify potential targets for new antiviral therapies. The research utilizes advanced molecular techniques to visualize these interactions in their natural environment, which could lead to the development of more effective treatments against COVID-19 variants. Patients may benefit from insights that could enhance vaccine efficacy and antibody therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been infected with SARS-CoV-2 or are at risk of infection, particularly those with underlying health conditions.
Not a fit: Patients who have not been exposed to SARS-CoV-2 or those with no risk factors for infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments and vaccines against COVID-19 variants.
How similar studies have performed: Other research has shown success in targeting conserved viral structures for vaccine development, indicating a promising approach in this area.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Grunst, Michael William — Yale University
- Study coordinator: Grunst, Michael William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.